Welcome. Already a member? Click here to sign in.
New customer? Click here  to begin.
Free Shipping on orders over $39.00
Vet Approved PET Medications - for LESS...   @VetApprovedRx.com
Call Toll Free: 877.847.7389
Show me products used for:   Dogs   Cats    > All <

Shop


Vetprofen is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

Vetprofen contains carprofen, the most widely used and clinically proven NSAID in veterinary medicine. Carprofen, like other NSAIDs, works by blocking the production of prostaglandins, the body chemicals that cause inflammation. Most dogs respond quickly to carprofen and become more active and mobile within just a few days of treatment
Add this item to your cart:

Item# Size/Desc Qty Price
800017
25mg per Caplet
$0.00
$0.37
  
This item requires a RX
800020
25mg 60 count bottle
$0.00
$25.99
This item requires a RX
800021
25mg 240 count bottle
$0.00
$88.99
Item qualifies for FREE SHIPPINGThis item requires a RX
800022
75mg per caplet
$0.00
$0.50
This item requires a RX
800023
75mg 60 count bottle
$0.00
$33.14
This item requires a RX
800024
75mg 240 count bottle
$0.00
$114.99
Item qualifies for FREE SHIPPINGThis item requires a RX
800025
100mg per caplet
$0.00
$0.60
This item requires a RX
800026
100mg 60 count bottle
$0.00
$42.99
Item qualifies for FREE SHIPPINGThis item requires a RX
800027
100mg 240 count bottle
$0.00
$135.99
Item qualifies for FREE SHIPPINGThis item requires a RX

**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.


DOSAGE AND ADMINISTRATION:
 
Carefully consider the potential benefits and risk of Vetprofen and other treatment options before deciding
to use Vetprofen.

Use the lowest effective dose for the shortest duration consistent with individual response.

The recommended dosage for oral administration to dogs is 2 mg/lb 4.4 mg/kg of body weight daily.

The total daily dose may be administered as 2 mg/lb of body weight once daily or divided and administered as 1 mg/lb2.2 mg/kg twice daily.
 
For the control of postoperative pain, administer approximately 2 hours before the procedure.
 
Caplets are scored and dosage should be calculated in half-caplet increments.


CONTRAINDICATIONS:

Vetprofen should not be used in dogs exhibiting previous hypersensitivity to carprofen.

WARNINGS:

Keep out of reach of children. Not for human use. Consult a physician in cases of accidental ingestion by humans. For use in dogs only. Do not use in cats.

All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered. Owners should be advised to observe for signs of potential drug toxicity

PRECAUTIONS:

As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Effects may result from decreased prostaglandin production and inhibition of the enzyme cyclooxygenase which is responsible for the formation of prostaglandins from arachidonic acid.11-14 When NSAIDs inhibit prostaglandins that cause inflammation they may also inhibit those prostaglandins which maintain normal homeostatic function. These anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease more often than in healthy patients.12,14 NSAID therapy could unmask occult disease which has previously been undiagnosed due to the absence of apparent clinical signs. Patients with underlying renal disease for example, may experience exacerbation or decompensation of their renal disease while on NSAID therapy.11-14 The use of parenteral fluids during surgery should be considered to reduce the potential risk of renal complications when using NSAIDs perioperatively.

Carprofen is an NSAID, and as with others in that class, adverse reactions may occur with its use. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be approached cautiously, with appropriate monitoring. Since many NSAIDs possess the potential to induce gastrointestinal ulceration, concomitant use of carprofen with other anti-inflammatory drugs, such as corticosteroids and NSAIDs, should be avoided or very closely monitored. Sensitivity to drug-associated adverse reactions varies with the individual patient. For example, carprofen treatment was not associated with renal toxicity or gastrointestinal ulceration in well-controlled safety studies of up to ten times the dose in dogs.

Carprofen is not recommended for use in dogs with bleeding disorders e.g., Von Willebrand's disease, as safety has not been established in dogs with these disorders. The safe use of carprofen in animals less than 6 weeks of age, pregnant dogs, dogs used for breeding purposes, or in lactating bitches has not been established. Studies to determine the activity of carprofen when administered concomitantly with other protein-bound or similarly metabolized drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring additional therapy. Such drugs commonly used include cardiac, anticonvulsant and behavioral medications. It has been suggested that treatment with carprofen may reduce the level of inhalant anesthetics needed.15

If additional pain medication is warranted after administration of the total daily dose of carprofen, alternative analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.

INFORMATION FOR DOG OWNERS

Vetprofen, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include decreased appetite, vomiting, diarrhea, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes.Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death .Owners should be advised to discontinue Vetprofen therapy and contact their veterinarian immediately if signs of intolerance are observed. The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID.

ADVERSE REACTIONS

During investigational studies of osteoarthritis with twice daily administration of 1 mg/lb, no clinically significant adverse reactions were reported. Some clinical signs were observed during field studies n=297 which were similar for carprofen- and placebo-treated dogs. Incidences of the following were observed in both groups: vomiting 4%, diarrhea 4%, changes in appetite 3%, lethargy 1.4%, behavioral changes 1%, and constipation 0.3%. The product vehicle served as control.

There were no serious adverse events reported during clinical field studies of osteoarthritis with once daily administration of 2 mg/lb. The following categories of abnormal health observations were reported. The product vehicle served as control.

Percentage of Dogs with Abnormal Health Observations Reported in Osteoarthritis Field Study 2 mg/lb once daily
Observation Carprofen n=129 Placebo n=132
Clinical pathology parameters listed represent reports of increases from pre-treatment values medical judgment is necessary to determine clinical relevance.
Inappetance 1.6 1.5
Vomiting 3.1 3.8
Diarrhea/Soft stool 3.1 4.5
Behavior change 0.8 0.8
Dermatitis 0.8 0.8
PU/PD 0.8 ----
SAP increase 7.8 8.3
ALT increase 5.4 4.5
AST increase 2.3 0.8
BUN increase 3.1 1.5
Bilirubinuria 16.3 12.1
Ketonuria 14.7 9.1

During investigational studies of surgical pain for the caplet formulation, no clinically significant adverse reactions were reported. The product vehicle served as control.

Percentage of Dogs with Abnormal Health Observations Reported in Surgical Pain Field Studies with Caplets 2 mg/lb once daily
Observation* Carprofen n=148 Placebo n=149
*
A single dog may have experienced more than one occurrence of an event
Vomiting 10.1 13.4
Diarrhea/Soft stool 6.1 6.0
Ocular disease 2.7 0
Inappetance 1.4 0
Dermatitis/skin lesion 2.0 1.3
Dysrhythmia 0.7 0
Apnea 1.4 0
Oral/periodontal disease 1.4 0
Pyrexia 0.7 1.3
Urinary tract disease 1.4 1.3
Wound drainage 1.4 0

Post-Approval Experience

Although not all adverse reactions are reported, the following adverse reactions are based on voluntary post-approval adverse drug experience reporting. The categories of adverse reactions are listed in decreasing order of frequency by body system.

Gastrointestinal: Vomiting, diarrhea, constipation, inappetence, melena, hematemesis, gastrointestinal ulceration, gastrointestinal bleeding, pancreatitis.

Hepatic: Inappetence, vomiting, jaundice, acute hepatic toxicity, hepatic enzyme elevation, abnormal liver function tests, hyperbilirubinemia, bilirubinuria, hypoalbuminemia. Approximately one-fourth of hepatic reports were in Labrador Retrievers.

Neurologic: Ataxia, paresis, paralysis, seizures, vestibular signs, disorientation.

Urinary: Hematuria, polyuria, polydipsia, urinary incontinence, urinary tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necrosis, renal tubular acidosis, glucosuria.

Behavioral: Sedation, lethargy, hyperactivity, restlessness, aggressiveness.

Hematologic: Immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, blood loss anemia, epistaxis.

Dermatologic: Pruritus, increased shedding, alopecia, pyotraumatic moist dermatitis hot spots, necrotizing panniculitis/vasculitis, ventral ecchymosis.

Immunologic or hypersensitivity: Facial swelling, hives, erythema.

In rare situations, death has been associated with some of the adverse reactions listed above.

To report a suspected adverse reaction call 1-800-835-9496.

ANIMAL SAFETY

Laboratory studies in unanesthetized dogs and clinical field studies have demonstrated that carprofen is well tolerated in dogs after oral administration.

In target animal safety studies, carprofen was administered orally to healthy Beagle dogs at 1, 3, and 5 mg/lb twice daily 1, 3 and 5 times the recommended total daily dose for 42 consecutive days with no significant adverse reactions. Serum albumin for a single female dog receiving 5 mg/lb twice daily decreased to 2.1 g/dL after 2 weeks of treatment, returned to the pre-treatment value 2.6 g/dL after 4 weeks of treatment, and was 2.3 g/dL at the final 6-week evaluation. Over the 6-week treatment period, black or bloody stools were observed in 1 dog 1 incident treated with 1 mg/lb twice daily and in 1 dog 2 incidents treated with 3 mg/lb twice daily. Redness of the colonic mucosa was observed in 1 male that received 3 mg/lb twice daily.

Two of 8 dogs receiving 10 mg/lb orally twice daily 10 times the recommended total daily dose for 14 days exhibited hypoalbuminemia. The mean albumin level in the dogs receiving this dose was lower 2.38 g/dL than each of 2 placebo control groups 2.88 and 2.93 g/dL, respectively. Three incidents of black or bloody stool were observed in 1 dog. Five of 8 dogs exhibited reddened areas of duodenal mucosa on gross pathologic examination. Histologic examination of these areas revealed no evidence of ulceration, but did show minimal congestion of the lamina propria in 2 of the 5 dogs.

In separate safety studies lasting 13 and 52 weeks, respectively, dogs were administered orally up to 11.4 mg/lb/day 5.7 times the recommended total daily dose of 2 mg/lb of carprofen. In both studies, the drug was well tolerated clinically by all of the animals. No gross or histologic changes were seen in any of the treated animals. In both studies, dogs receiving the highest doses had average increases in serum L-alanine aminotransferase ALT of approximately 20 IU.

In the 52 week study, minor dermatologic changes occurred in dogs in each of the treatment groups but not in the control dogs. The changes were described as slight redness or rash and were diagnosed as nonspecific dermatitis. The possibility exists that these mild lesions were treatment related, but no dose relationship was observed.

Clinical field studies were conducted with 549 dogs of different breeds at the recommended oral doses for 14 days 297 dogs were included in a study evaluating 1 mg/lb twice daily and 252 dogs were included in a separate study evaluating 2 mg/lb once daily. In both studies the drug was clinically well tolerated and the incidence of clinical adverse reactions for carprofen- treated animals was no higher than placebo-treated animals placebo contained inactive ingredients found in carprofen. For animals receiving 1 mg/lb twice daily, the mean post-treatment serum ALT values were 11 IU greater and 9 IU less than pre-treatment values for dogs receiving carprofen and placebo, respectively. Differences were not statistically significant. For animals receiving 2 mg/lb once daily, the mean post-treatment serum ALT values were 4.5 IU greater and 0.9 IU less than pre-treatment values for dogs receiving carprofen and placebo, respectively. In the latter study, 3 carprofen- treated dogs developed a 3-fold or greater increase in ALT and/or AST during the course of therapy. One placebo-treated dog had a greater than 2-fold increase in ALT. None of these animals showed clinical signs associated with laboratory value changes. Changes in the clinical laboratory values hematology and clinical chemistry were not considered clinically significant. The 1 mg/lb twice daily course of therapy was repeated as needed at 2-week intervals in 244 dogs, some for as long as 5 years.

Clinical field studies were conducted in 297 dogs of different breeds undergoing orthopedic or soft tissue surgery. Dogs were administered 2 mg/lb of carprofen two hours prior to surgery then once daily, as needed for 2 days soft tissue surgery or 3 days orthopedic surgery. Carprofen was well tolerated when used in conjunction with a variety of anesthetic-related drugs. The type and severity of abnormal health observations in carprofen-and placebo-treated animals were approximately equal and few in number . The most frequent abnormal health observation was vomiting and was observed at approximately the same frequency in carprofen- and placebo- treated animals. Changes in clinicopathologic indices of hematopoetic, renal, hepatic, and clotting function were not clinically significant. The mean post-treatment serum ALT values were 7.3 IU and 2.5 IU less than pre-treatment values for dogs receiving carprofen and placebo, respectively. The mean post-treatment AST values were 3.1 IU less for dogs receiving carprofen and 0.2 IU greater for dogs receiving placebo.

STORAGE

Store at controlled room temperature 15°C - 30°C 59°F - 86°F.